Cargando…

First In-Human Medical Imaging with a PASylated (89)Zr-Labeled Anti-HER2 Fab-Fragment in a Patient with Metastatic Breast Cancer

PURPOSE: PASylation® offers the ability to systematically tune and optimize the pharmacokinetics of protein tracers for molecular imaging. Here we report the first clinical translation of a PASylated Fab fragment ((89)Zr∙Df-HER2-Fab-PAS(200)) for the molecular imaging of tumor-related HER2 expressio...

Descripción completa

Detalles Bibliográficos
Autores principales:	Richter, Antonia, Knorr, Karina, Schlapschy, Martin, Robu, Stephanie, Morath, Volker, Mendler, Claudia, Yen, Hsi-Yu, Steiger, Katja, Kiechle, Marion, Weber, Wolfgang, Skerra, Arne, Schwaiger, Markus
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Singapore 2020
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7198682/ https://www.ncbi.nlm.nih.gov/pubmed/32377263 http://dx.doi.org/10.1007/s13139-020-00638-7

Ejemplares similares

High contrast tumor imaging with radio-labeled antibody Fab fragments tailored for optimized pharmacokinetics via PASylation
por: Mendler, Claudia T, et al.
Publicado: (2014)

Effective rational humanization of a PASylated anti-galectin-3 Fab for the sensitive PET imaging of thyroid cancer in vivo
por: Peplau, Emanuel, et al.
Publicado: (2021)

PASylation: a biological alternative to PEGylation for extending the plasma half-life of pharmaceutically active proteins
por: Schlapschy, Martin, et al.
Publicado: (2013)

Improvement of Certolizumab Fab′ properties by PASylation technology
por: Mazaheri, Somayeh, et al.
Publicado: (2020)

PASylated Thymosin α1: A Long-Acting Immunostimulatory Peptide for Applications in Oncology and Virology
por: Binder, Uli, et al.
Publicado: (2020)

Direct Affinity Purification of Long‐Acting PASylated Proteins with Therapeutic Potential Using L‐Prolinamide for Mild Elution
por: Schilz, Jonas, et al.
Publicado: (2022)

Type I IFN signaling blockade by a PASylated antagonist during chronic SIV infection suppresses specific inflammatory pathways but does not alter T cell activation or virus replication
por: Nganou-Makamdop, Krystelle, et al.
Publicado: (2018)

Single chain Fab (scFab) fragment
por: Hust, Michael, et al.
Publicado: (2007)

Development of [(89)Zr]Zr-hCD103.Fab01A and [(68)Ga]Ga-hCD103.Fab01A for PET imaging to noninvasively assess cancer reactive T cell infiltration: Fab-based CD103 immunoPET
por: Fan, Xiaoyu, et al.
Publicado: (2023)

Toward Optimized (89)Zr-Immuno-PET: Side-by-Side Comparison of [(89)Zr]Zr-DFO-, [(89)Zr]Zr-3,4,3-(LI-1,2-HOPO)- and [(89)Zr]Zr-DFO*-Cetuximab for Tumor Imaging: Which Chelator Is the Most Suitable?
por: Damerow, Helen, et al.
Publicado: (2022)

Comparative in vivo biodistribution of cells labelled with [(89)Zr]Zr-(oxinate)(4) or [(89)Zr]Zr-DFO-NCS using PET
por: Friberger, Ida, et al.
Publicado: (2023)

(89)Zr-Immuno-Positron Emission Tomography in Oncology: State-of-the-Art (89)Zr Radiochemistry
por: Heskamp, Sandra, et al.
Publicado: (2017)

Development of a high affinity Anticalin(®) directed against human CD98hc for theranostic applications
por: Deuschle, Friedrich-Christian, et al.
Publicado: (2020)

HER3 PET Imaging: (68)Ga-Labeled Affibody Molecules Provide Superior HER3 Contrast to (89)Zr-Labeled Antibody and Antibody-Fragment-Based Tracers
por: Rinne, Sara S., et al.
Publicado: (2021)

Potential and pitfalls of (89)Zr-immuno-PET to assess target status: (89)Zr-trastuzumab as an example
por: Huisman, Marc C., et al.
Publicado: (2021)

Imaging EGFR and HER3 through (89)Zr-labeled MEHD7945A (Duligotuzumab)
por: McKnight, Brooke N., et al.
Publicado: (2018)

Production of single chain Fab (scFab) fragments in Bacillus megaterium
por: Jordan, Eva, et al.
Publicado: (2007)

Structure of the human heterodimeric transporter 4F2hc-LAT2 in complex with Anticalin, an alternative binding protein for applications in single-particle cryo-EM
por: Jeckelmann, Jean-Marc, et al.
Publicado: (2022)

A Semi Rigid Novel Hydroxamate AMPED-Based Ligand for (89)Zr PET Imaging
por: Russelli, Lisa, et al.
Publicado: (2021)

Current Perspectives on (89)Zr-PET Imaging
por: Yoon, Joon-Kee, et al.
Publicado: (2020)

Optimisation of the Synthesis and Cell Labelling Conditions for [(89)Zr]Zr-oxine and [(89)Zr]Zr-DFO-NCS: a Direct In Vitro Comparison in Cell Types with Distinct Therapeutic Applications
por: Friberger, Ida, et al.
Publicado: (2021)

(89)Zr-mAb3481 PET for HER3 tumor status assessment during lapatinib treatment
por: Pool, Martin, et al.
Publicado: (2017)

(89)Zr-immuno-PET using the anti-LAG-3 tracer [(89)Zr]Zr-BI 754111: demonstrating target specific binding in NSCLC and HNSCC
por: Miedema, Iris H.C., et al.
Publicado: (2023)

DutaFabs are engineered therapeutic Fab fragments that can bind two targets simultaneously
por: Beckmann, Roland, et al.
Publicado: (2021)

Correction: Optimisation of the Synthesis and Cell Labelling Conditions for [89Zr]Zr-oxine and [89Zr]Zr-DFO-NCS: a Direct In Vitro Comparison in Cell Types with Distinct Therapeutic Applications
por: Friberger, Ida, et al.
Publicado: (2022)

Production of Antibody Fab Fragments in Escherichia coli
por: Tachibana, Hiroshi, et al.
Publicado: (2011)

Monitoring Src status after dasatinib treatment in HER2+ breast cancer with (89)Zr-trastuzumab PET imaging
por: McKnight, Brooke N., et al.
Publicado: (2018)

Synthesis of a novel (89)Zr-labeled HER2 affibody and its application study in tumor PET imaging
por: Xu, Yuping, et al.
Publicado: (2020)

Therapeutic Response Monitoring with (89)Zr-DFO-Pertuzumab in HER2-Positive and Trastuzumab-Resistant Breast Cancer Models
por: Kang, Minwoo, et al.
Publicado: (2022)

Evaluation of (89)Zr-pertuzumab in Breast Cancer Xenografts
por: Marquez, Bernadette V., et al.
Publicado: (2014)

Heptadentate chelates for (89)Zr-radiolabelling of monoclonal antibodies
por: Guillou, Amaury, et al.
Publicado: (2022)

Development and evaluation of (89)Zr-trastuzumab for clinical applications
por: Mohammadpour-Ghazi, Fatemeh, et al.
Publicado: (2023)

PASylated Urate Oxidase Enzyme: Enhancing Biocatalytic Activity, Physicochemical Properties, and Plasma Half-Life
por: Najjari, Abbas, et al.
Publicado: (2022)

Bicistronic DNA display for in vitro selection of Fab fragments
por: Sumida, Takeshi, et al.
Publicado: (2009)

Annotating MYC oncogene status with (89)Zr-transferrin imaging
por: Holland, Jason P., et al.
Publicado: (2012)

Microfluidic Preparation of (89)Zr-Radiolabelled Proteins by Flow Photochemistry
por: Earley, Daniel F., et al.
Publicado: (2021)

Noninvasive Imaging of PSMA in Prostate Tumors with (89)Zr-Labeled huJ591 Engineered Antibody Fragments: The Faster Alternatives
por: Viola-Villegas, Nerissa Therese, et al.
Publicado: (2014)

A single-domain antibody-linked Fab bispecific antibody Her2-S-Fab has potent cytotoxicity against Her2-expressing tumor cells
por: Li, Aifen, et al.
Publicado: (2016)

PET Imaging of Small Extracellular Vesicles via [(89)Zr]Zr(oxinate)(4) Direct Radiolabeling
por: Khan, Azalea A., et al.
Publicado: (2022)

Dosimetric evaluation and radioimmunotherapy of anti-tumour multivalent Fab́ fragments
por: Casey, J L, et al.
Publicado: (1999)

Cannot write session to /tmp/vufind_sessions/sess_7ucp1bnsvp0f620alq39nm92iv